GLP-1 Drugs: Risks, Benefits & Biomarker Assessment

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists have generated significant clinical benefit for weight management and cardiometabolic health, yet they carry documented risks including gastrointestinal side effects, pancreatitis risk, and thyroid concerns. Recent data show approximately 25–30% of users experience moderate-to-severe nausea early in therapy, while serious adverse events remain rare in clinical populations. Understanding both the evidence and your individual risk profile is essential before starting treatment.

PlexusDx supports precision-wellness by combining clinical safety assessment with biomarker and genetic context. Rather than a one-size-fits-all approach, knowing your metabolic markers and peptide-pathway genetic predispositions—alongside comprehensive medical evaluation—can help guide whether GLP-1 therapy is appropriate for you and which formulation or dosing strategy may optimize benefit while minimizing risk.

Documented Benefits: Clinical Evidence and Metabolic Outcomes

GLP-1 receptor agonists consistently demonstrate weight loss of 10–22% body weight depending on dose, agent, and adherence. In the SUSTAIN 6 trial (semaglutide), cardiovascular events were reduced by 26% in patients with established cardiovascular disease. Glycemic control improves in 60–80% of patients with type 2 diabetes, and some agents show cardio-protective properties independent of weight loss.

Beyond weight and glucose, GLP-1s may improve blood pressure, triglyceride levels, and inflammatory markers. Many patients report improved appetite control and sustained satiety at lower caloric intake, which supports long-term behavior change. These benefits extend to both diabetic and non-diabetic populations, though mechanism of action and magnitude differ by individual.

Common and Serious Adverse Events: What the Evidence Shows

The most frequent side effects are gastrointestinal: nausea (40–50% of users), vomiting (10–15%), constipation (20–30%), and diarrhea (15–20%). These often resolve within weeks but can be severe enough to cause discontinuation in 5–10% of patients. Rare but serious events include acute pancreatitis (incidence approximately 0.1%), medullary thyroid carcinoma (in preclinical animal models, contraindicated in certain populations), and retinopathy worsening in advanced diabetes.

Adverse Event	Frequency	Severity Profile	Clinical Action
Nausea/vomiting	40–50% early therapy	Usually mild–moderate, resolves weeks 3–8	Dose titration, dietary adjustment
Constipation/diarrhea	20–30%	Mild–moderate, varies by individual	Hydration, dietary fiber, laxatives as needed
Acute pancreatitis	~0.1%	Potentially serious; seek immediate care	Discontinue; evaluate amylase/lipase if abdominal pain
Gallbladder disease	1–2% incidence	Ranges from asymptomatic to symptomatic	Ultrasound evaluation if advised by provider

Biomarkers That Inform GLP-1 Candidacy and Risk Stratification

Baseline biomarkers help evaluate safety and predict response. Fasting glucose, HbA1c, lipid panel, liver enzymes, renal function, and inflammatory markers (hsCRP, TNF-α) provide metabolic context. Patients with elevated amylase or lipase, severe liver disease, or renal impairment may face higher risk. Those with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindicated.

Biomarker trends during early therapy—such as sustained gastrointestinal symptoms, rapid lipase elevation, or worsening kidney function—warrant provider reassessment. PlexusDx's Precision Peptide Genetic Test can reveal predispositions in GLP-1 receptor (GLP1R) and GIPR pathways, providing context for how your genetic background may influence response variability and tolerability, though genetics alone do not predict exact medication outcomes.

Who Should Avoid GLP-1 Therapy and Who May Benefit Most

Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe pancreatitis history, and severe renal disease (eGFR <15). Relative cautions apply to patients with diabetic retinopathy requiring rapid glycemic control, gastroparesis, or inflammatory bowel disease. Pregnancy and breastfeeding are contraindications, as animal studies suggest fetal risk.

GLP-1 therapy may be most beneficial for patients with overweight/obesity plus type 2 diabetes, hypertension, or established cardiovascular disease who have failed lifestyle modification alone. Those with lower baseline gastrointestinal sensitivity, better medication adherence, and provider support for titration often achieve sustained benefit. A comprehensive medical evaluation and discussion of your medical history, medications, and goals with your healthcare provider is essential before initiating any GLP-1 agent.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test evaluates key variants in GLP-1 receptor (GLP1R rs6923761) and glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437) pathways. These variants may help provide context about your genetic predisposition to GLP-1 receptor signaling efficiency. This information should be interpreted with a qualified healthcare provider alongside biomarkers and clinical assessment to support a more informed conversation about GLP-1 candidacy.

The Precision Peptide Genetic Test also includes variants in FTO (rs9939609) and MC4R (rs17782313) genes, which relate to metabolic regulation and appetite control. Understanding your genetic profile in these pathways can support discussions with your provider about expected response patterns and whether GLP-1 therapy aligns with your metabolic predispositions. Genetics reveal predispositions—not definitive outcomes—and must be combined with clinical evaluation.

Compounded semaglutide and tirzepatide from PlexusDx's licensed 503A pharmacies offer flexible dosing and cost-effective access for patients and providers assessing GLP-1 therapy. Using genetic and biomarker insights alongside comprehensive provider guidance ensures that your treatment plan addresses both efficacy and safety, supporting a more personalized approach to metabolic wellness.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.